PostEra GTM brain

PostEra develops small-molecule medicines using its Proton AI medicinal chemistry platform and partnerships with biopharma organizations.

category

AI medicinal chemistry and drug discovery

market profile

  • text: Drug development is lengthy and failure-prone, with medicinal chemistry iterating through design, make and test.
  • text: Partnerships and internal programs both form part of the business; Pfizer has expanded an AI discovery collaboration.

personas

  • title: Head of medicinal chemistry
    pains:
    • Optimizing potency, selectivity and other properties simultaneously
    • Compounds proposed by models may be difficult or slow to synthesize
  • title: Biopharma R&D or discovery alliance leader
    pains:
    • Preclinical discovery takes too long and too much capital
    • External AI claims need validation in real programs
  • title: Computational chemistry lead
    pains:
    • Sparse and noisy experimental data weakens model decisions
    • Prioritizing which compounds to make and test consumes scarce lab capacity

icp

  • text: Pharmaceutical companies with established discovery programs and small-molecule targets, including large multinational R&D organizations.
  • text: Biotech and research organizations seeking a partner to progress small molecule targets to development candidates.

message pillars

  • text: Machine learning is applied specifically to medicinal chemistry.
  • text: Proton connects the full discovery cycle.
  • text: Molecule design includes practical synthetic routes.
  • text: Model choices aim to maximize information gained from experiments.

objections

  • objection: How do we know the AI works on real medicinal chemistry?
    response: Evaluate publications and partner case studies alongside a defined prospective program and agreed endpoints.
  • objection: Will proposed molecules actually be synthesizable?
    response: Review the proposed synthetic routes and shared intermediates with the chemistry team.
  • objection: What are the commercial terms and ownership?
    response: Discuss target scope, milestones and rights directly with business development; terms are program specific.

competitors

  • name: Insilico Medicine
    why: AI-enabled drug discovery and internal therapeutics pipeline.
  • name: Isomorphic Labs
    why: Partners with pharma on AI-driven drug design.
  • name: insitro
    why: Machine learning-driven discovery competes for biopharma collaborations.

influencers

  • name: Alpha Lee
    url: https://postera.ai/
    why: Chief scientific officer and co-founder representing the platform's science.
  • name: Aaron Morris
    url: https://cen.acs.org/pharmaceuticals/PostEra-designs-drugs-from-code/103/web/2025/11
    why: CEO and co-founder discussing business and discovery partnerships.

keywords

  • AI medicinal chemistry
  • small molecule drug discovery partnership
  • design make test machine learning
  • AI retrosynthesis drug discovery
  • lead optimization AI
  • drug discovery collaboration

voice

  • Scientific and evidence-led
  • Direct about discovery bottlenecks
  • Optimistic about patient impact

signals

  • text: A pharma team is seeking external AI partners for preclinical small molecule design.
  • text: An existing discovery program is constrained by slow synthesis or competing molecular properties.

stack

  • Proton chemistry foundation models
  • active learning

pricing

model: unknown

motion

sales_led

channels

  • Scientific publications
  • pharma partnerships
  • LinkedIn
  • press
  • business development

confidence

high

Founders

  • name: Aaron Morris
    title: Founder
    role: Founder
    bio: CEO at PostEra
  • name: Alpha Lee
    title: Founder
    role: Founder
  • name: Matthew Robinson
    title: Founder
    role: Founder

Back to YC companies